Mirum Pharma's Phase 2b Study Of Volixibat For Sclerosing Cholangitis Meets End Point, Shares Gain
4/5 14:52
(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The company said the result support the potential for Volixibat as the first treatment for...